Published • loading... • Updated
Germany’s Merck Buys Silence Therapeutics for $1.3 Billion
Merck will pay $20 per share, a 130% premium, to add Silence’s siRNA platform and rare-disease pipeline to its specialty medicines business.
- On Monday, Merck KGaA announced it will acquire British biotech company Silence Therapeutics in an all-cash deal valued at about $1.3 billion, expanding its portfolio of specialty and rare disease medicines.
- Silence develops siRNA, a specialized medicine that acts like a "mute button" for faulty genes inside the body, technology Merck plans to integrate to treat challenging conditions.
- Merck will pay $20 per share for Silence, representing a 130% premium to the stock's last close, with the transaction valued at around $1.1 billion enterprise value based on $6.67 per ordinary share.
- Following the announcement, Silence shares climbed 4% in premarket trading, with the all-cash deal expected to close in the first quarter of 2027 subject to regulatory approvals.
- Merck CEO Kai Beckmann stated the acquisition will strengthen capabilities to serve patients with targeted specialty and rare diseases, saying "we are advancing our efforts to build a differentiated, sustainable pipeline.
Insights by Ground AI
23 Articles
23 Articles
The pharmaceutical and technology group is taking the next acquisition under its new boss Kai Beckmann. Merck is to advance the deal in the rare disease business.
volksfreund.deReposted by 
saarbruecker-zeitung.de
saarbruecker-zeitung.deThe pharmaceutical and technology group is taking the next acquisition under its new boss Kai Beckmann. Merck is to advance the deal in the rare disease business.
The pharmaceutical and technology group Merck acquires a British biotech group. This is intended to boost the business for drugs against rare diseases.
·Düsseldorf, Germany
Read Full ArticleCoverage Details
Total News Sources23
Leaning Left1Leaning Right4Center6Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
C 55%
R 36%
Factuality
To view factuality data please Upgrade to Premium
